Announced Tue, 26 Aug · 19:41 IST

Submission of letter dispatched to the shareholders in compliance of Regulation 36 (1) (b) of SEBI (LODR) Reg. 2015

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Novelix Pharmaceuticals has informed BSE that it has dispatched a letter to its shareholders in compliance with Regulation 36(1)(b) of the SEBI (LODR) Regulations, 2015. This regulation requires companies to send shareholders a letter along with the notice of a general meeting, typically covering details of directors seeking appointment or reappointment and other relevant items on the meeting agenda. The filing is a routine corporate governance disclosure confirming the dispatch of this communication. No new business decision, financial result, or board action is announced in this particular submission.

Likely market impact

This is a routine regulatory compliance filing with no direct material impact on the stock price or shareholder value. Investors should watch for the accompanying general meeting notice for any substantive items such as director appointments, special resolutions, or financial approvals.